Atrial Fibrillation
and ischemic stroke
Undetected AF puts stroke victims at a higher likelihood for recurrent stroke and may go undetected during standard clinical work up. Ischemia Care is addressing this clinical need.
Read more
Cryptogenic
= no cause determined
Cause of ischemic stroke is unkown in up to 40% of cases, increasing recurrence risk. Knowing cause will lead to improved outcomes and reduced costs.
Read more
Ischemia Care
blood test for stroke
leading to timely diagnosis and treatment, including "point of care", resulting in improved patient care and hospital cost savings.
Read more
Clinical stage, venture backed, diagnostic laboratory company commercializing a pipeline of blood tests for cause of stroke.
40% of ischemic strokes never have cause determined. Knowing cause of stroke is critical to patient outcomes and reducing costs.
Ischemia Care's pipeline is based upon over 15 years of publications in major peer reviewed journals with sensitivity and specificty > 95%.
The BASE clinical trial will serve as a final clinical validation and increase early adoption through the company CLIA laboratory.

About BASE

BASE (NCT02014896) is a prospective trial designed to validate over 15 years of peer reviewed clinical findings leading to commercilization of a platform of diagnostic testing, including point of care.
Read more

Leadership Team

Proven management team and advisors (2 IPOs, multiple exits, former Chief of Cardiology at Stanford), KOLs in the field of stroke (author of Stroke Guidelines), strategic support (Affymetrix, Medtronics), and leading stroke centers.
Read more

Recent News and Notes

June 2016 - Ischemia Care successfully develops blood based signature for cause of stroke

Using RNA expression from whole blood, ISC has developed a gene based classifier (or signature) to differentaite cardioembolic from atheroembolic (large vessel) ischemic stroke.

Sept 2016 - BASE clinical trial recruitment exceeding expectations

Over 900 subjects enrolled and over 3,500 samples collected in BASE since December 2013, making BASE one of the most successful biomarker or stroke clinical trials.

Sept 2016 - Ischemia Care closes funding round

Company closes on a $1.7M round to support commercilization.
Read more